Patents by Inventor Zhijian Lu

Zhijian Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180215752
    Abstract: Certain tetrahydro-azepinoquinolines of structural formula I are agonists of the mammalian 5-HT2c receptor, and, in particular, are selective agonists of the mammalian 5-HT2c receptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-HT2c receptor, such as obesity, obesity-related conditions, and certain CNS-related disorders, including schizophrenia and depression. They are also useful as aids for tobacco smoking cessation.
    Type: Application
    Filed: August 26, 2015
    Publication date: August 2, 2018
    Applicant: Sunnylife Pharma, Inc.
    Inventors: Jonathan A. Groeper, Xibin Liao, Zhijian Lu
  • Patent number: 9877957
    Abstract: The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardio renal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: January 30, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason Imbriglio, Clare London, Zhijian Lu, James Tata, Yusheng Xiong, Ming You, Hyewon Youm
  • Patent number: 9869811
    Abstract: This disclosure provides a method for manufacturing a large-version light guide sheet using a mask plate. The method includes adopting a mask plate containing a plurality of regions, performing selective polymerization on a photopolymerizable material mixture which is coated on a large-version light guide substrate (401) by means of the mask plate, and forming a raised or depressed microstructure (402) on the large-version light guide substrate (401), so as to constitute a large-version light guide sheet. The large-version light guide sheet comprises a plurality of units (U11, U12, U13, U14). By dividing the large-version light guide sheet, a plurality of discrete unit light guide sheets that are used for an LCD backlight source and an LED lighting assembly are obtained. The method overcomes the limitations of ink jet printing, injection molding, laser etching and other technologies, and improves the production rate of high-performance thinned light guide sheets.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: January 16, 2018
    Assignee: BRIVU TECHNOLOGIES CO., LTD
    Inventors: Zhijian Lu, Xing Yang, Yarong Zhang, Yunsheng Yang
  • Patent number: 9828369
    Abstract: The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardio-renal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: November 28, 2017
    Assignee: Merck Sharpe & Dohme Corp.
    Inventors: Jason Imbriglio, Clare London, Zhijian Lu, James Tata, Yusheng Xiong, Ming You, Hyewon Youm
  • Publication number: 20170275274
    Abstract: The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardio-renal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
    Type: Application
    Filed: August 31, 2015
    Publication date: September 28, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jason Imbriglio, Clare London, Zhijian Lu, James Tata, Yusheng Xiong, Ming You, Hyewon Youm
  • Publication number: 20170273966
    Abstract: The present invention relates to a compound represented by formula I:and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardio renal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
    Type: Application
    Filed: August 31, 2015
    Publication date: September 28, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jason Imbriglio, Clare London, Zhijian Lu, James Tata, Yusheng Xiong, Ming You, Hyewon Youm
  • Publication number: 20160075724
    Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
    Type: Application
    Filed: October 5, 2015
    Publication date: March 17, 2016
    Inventors: Amjad Ali, Joann M. Napolitano, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Hallet, Christopher F. Thompson, Nazia Quraishi, Cameron J. Smith, Julianne A. Hunt, Adrian A. Dowst, Yi-Heng Chen, Hong Li
  • Patent number: 9221834
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substituted phenyl group or indanyl group. Formula (I).
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: December 29, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Zhijian Lu, Yi-Heng Chen, Cameron Smith, Hong Li, Christopher F. Thompson, Julianne Hunt, Florida Kallashi, Ramzi Sweis, Peter Sinclair, Samantha E. Adamson, Guizhen Dong, Debra L. Ondeyka, Xiaoxia Qian, Wanying Sun, Petr Vachal, Kake Zhao
  • Publication number: 20150323730
    Abstract: A method for manufacturing a large-version light guide sheet using a mask plate, comprising: adopting a mask plate containing a plurality of regions, performing selective polymerization on a photopolymerizable material mixture which is coated on a large-version light guide substrate (401) by means of the mask plate, and forming a raised or depressed microstructure (402) on the large-version light guide substrate (401), so as to constitute a large-version light guide sheet. The large-version light guide sheet comprises a plurality of units (U11, U12, U13, U14). By dividing the large-version light guide sheet, a plurality of discrete unit light guide sheets that are used for an LCD backlight source and an LED lighting assembly are obtained. The method overcomes the limitations of ink jet printing, injection molding, laser etching and other technologies, and improves the production rate of high-performance thinned light guide sheets.
    Type: Application
    Filed: April 24, 2013
    Publication date: November 12, 2015
    Inventors: Zhijian LU, Xing YANG, Yarong ZHANG, Yunsheng YANG
  • Publication number: 20140221383
    Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
    Type: Application
    Filed: April 14, 2014
    Publication date: August 7, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann M. Napolitano, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Hallet, Christopher F. Thompson, Nazia Quraishi, Cameron J. Smith, Julianne A. Hunt, Adrian A. Dowst, Yi-Heng Chen, Hong Li
  • Patent number: 8735435
    Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: May 27, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann M. Napolitano, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Hallett, Christopher F. Thompson, Nazia Quraishi, Cameron J. Smith
  • Publication number: 20130331372
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substituted phenyl group or indanyl group. Formula (I).
    Type: Application
    Filed: October 25, 2011
    Publication date: December 12, 2013
    Inventors: Zhijian Lu, Yi-Heng Chen, Cameron Smith, Hong Li, Christopher F. Thompson, Julianne Hunt, Florida Kallashi, Ramzi Sweis, Peter Sinclair, Samantha E. Adamson, Guizhen Dong, Debra L. Ondeyka, Xiaoxia Qian, Wanying Sun, Petr Vachal, Kake Zhao
  • Patent number: 8440702
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: May 14, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Zhijian Lu, Peter J. Sinclair, Yi-Heng Chen, Cameron J. Smith, Hong Li
  • Patent number: 8409789
    Abstract: A large mask with random apertures may be formed by forming a smaller mask (also called a cell mask) with a random pattern of transmissive apertures which is then repeatedly replicated to create the large mask. The random pattern may be created by perturbing the aperture locations by a small amount or the apertures may be randomly placed within the cell mask provided certain criteria are met. Alternatively, a large mask with a random pattern of transmissive apertures may be formed without using a cell mask. This large mask may be used to fabricate diffusers and other devices that do not suffer from the interference, diffraction and other optical effects common in devices having structures that are non-randomly patterned.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: April 2, 2013
    Inventor: Zhijian Lu
  • Publication number: 20120322104
    Abstract: The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XBP1- or ATF6-mediated UPR pathway.
    Type: Application
    Filed: April 13, 2012
    Publication date: December 20, 2012
    Applicant: Wyeth LLC
    Inventors: Yijie GAO, Nicloe M. Piche, Mei Geng, Stephen H. Herrmann, Xiaotian Zhong, Ronald Kriz, Zhijian Lu
  • Patent number: 8321869
    Abstract: The present specification describes techniques and apparatus that enable synchronization using agent-based semaphores. In one or more implementations, a semaphore is used for a first agent to notify a second agent that the first agent has completed a particular task of a set of tasks and has completed using a shared resource for the particular task.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: November 27, 2012
    Assignee: Marvell International Ltd.
    Inventors: Junqiang Lan, Li Sha, Zhijian Lu, Ye Zhou
  • Patent number: 8193365
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: June 5, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann Bohn, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle Taylor, Christopher Thompson, Nazia Quraishi
  • Patent number: 8173394
    Abstract: The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XB1- or ATF6-mediated UPR pathway.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: May 8, 2012
    Assignee: Wyeth LLC
    Inventors: Yijie Gao, Nicole M. Piche, Mei Geng, Stephen H. Herrmann, Xiaotian Zhong, Ronald Kriz, Zhijian Lu
  • Patent number: 8101282
    Abstract: Diffusers including of a plurality of protruded structures with each structure containing multiple rugged facets are disclosed. The diffuser may be fabricated by coating a mixture of materials on a carrier film, the mixture of materials including at least a first material that polymerizes upon irradiation and at least a second material that is incompatible with the first material in polymerized form, then selectively irradiating the mixture of materials to polymerize a portion of the mixture of materials to form polymerized structures, and finally removing that part of the mixture of materials not forming part of the structures. A transparent material may be coated over the structures. The overcoat material may further contain scattering elements such as glass beads or polymeric particles.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: January 24, 2012
    Inventor: Zhijian Lu
  • Publication number: 20110178059
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.
    Type: Application
    Filed: March 28, 2011
    Publication date: July 21, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad ALI, Zhijian Lu, Peter J. Sinclair, Yi-Heng Chen, Cameron J. Smith, Hong Li